B1 receptors as a new inflammatory target. Could this B the 1?

Trends in Pharmacological Sciences

Volumn 20, Issue 3, 1999, Pages 100-104

  Ahluwalia, Amrita ^a   Perretti, Mauro ^b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

3 (6 ACETAMIDO 3 PYRIDYL) N [N [2,4 DICHLORO 3 [(2 METHYL 8 QUINOLINYL)OXYMETHYL]PHENYL] N METHYLAMINOCARBONYLMETHYL]ACRYLAMIDE; BRADYKININ; BRADYKININ B1 RECEPTOR; BRADYKININ B1 RECEPTOR ANTAGONIST; ICATIBANT; PARTIAL AGONIST; RECEPTOR SUBTYPE; [[4 [2 [[BIS(CYCLOHEXYLAMINO)METHYLENE]AMINO] 3 (2 NAPHTHYL)PROPIONAMIDO]PHENYL]METHYL]TRIBUTYLPHOSPHONIUM CHLORIDE; ANTIINFLAMMATORY AGENT; BRADYKININ RECEPTOR;

EDEMA; HUMAN; HUMAN CELL; INFLAMMATION; PAIN; PRIORITY JOURNAL; REVIEW; TISSUE INJURY; ANIMAL; ARTICLE; CELL MOTION; CLASSIFICATION; DRUG ANTAGONISM; PATHOLOGY; PHYSIOLOGY;

ANIMALS; ANTI-INFLAMMATORY AGENTS; BRADYKININ; CELL MOVEMENT; EDEMA; HUMANS; INFLAMMATION; PAIN; RECEPTORS, BRADYKININ;

EID: 0032588354     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-6147(99)01321-8     Document Type: Note

References (36)

1. Rocha e Silva, M., Beraldo, W. T. and Rosenfeld, G. (1949) Am. J. Physiol. 156, 261-273
2. Lewis, G. P. (1963) Ann. New York Acad. Sci. 104, 236-249
3. Bhoola, K. D., Figueroa, C. D. and Worthy, K. (1992) Pharmacol. Rev. 44, 1-79
4. Menke, J. G. et al. (1994) J. Biol. Chem. 269, 21583-21586
5. Hess, J. F., Borkowski, J. A., Young, G. S., Strader, C. D. and Ransom, R. W. (1994) Mol. Pharmacol. 45, 1-8
6. Steranka, L. R. et al. (1988) Proc. Natl. Acad. Sci. U. S. A. 85, 3245-3249
7. Regoli, D., Allogha, S. N., Rizzi, A. and Gobeil, F., Jr (1998) Eur. J. Pharmacol. 348, 1-10
8. MacNeil, T. et al. (1995) Biochim. Biophys. Acta 1264, 223-228
9. Pesquero, J. B. et al. (1996) Biochem. Biophys. Res. Commun. 220, 219-225
10. Ni, A., Chao, L. and Chao, J. (1998) J. Biol. Chem. 273, 2784-2791
11. Schanstra, J. P. (1998) J. Clin. Invest. 101, 2080-2091
12. Pan, Z. K. (1996) J. Clin. Invest. 98, 2042-2049
13. Campos, M. M. and Calixto, J. B. (1995) Br. J. Pharmacol. 114, 1005-1013
14. Austin, C. E. et al. (1997) J. Biol. Chem. 272, 11420-11425
15. Madeddu, P. et al. (1997) Circulation 96, 3570-3578
16. Boyce, S. et al. (1996) Immunopharmacology 33, 333-335
17. Regoli, D., Marceau, F. and Barabe, J. (1978) Can. J. Physiol. Pharmacol. 56, 674-677
18. Regoli, D., Marceau, F. and Lavigne, J. (1981) Can. J. Physiol. Pharmacol. 71, 105-115
19. Regoli, D. and Barabe, J. (1980) Pharmacol. Rev. 32, 1-46
20. Vavrek, R. and Stewart, J. M. (1985) Peptides 6, 161-164
21. Hock, F. J. et al. (1991) Br. J. Pharmacol. 769, 769-773
22. Inamura, N. et al. (1997) Can. J. Physiol. Pharmacol. 75, 622-628
23. Wirth, K. et al. (1991) Br. J. Pharmacol. 102, 774-777
24. Marceau, F. (1997) in The Kinin System (Farmer, S. G., ed.), pp. 143-156, Academic Press
25. Raymond, P. et al. (1995) J. Immunol. Methods 180, 247-257
26. Schremmer-Daninger, F., Offner, A., Siebeck, M. and Roscher, A. A. (1998) Biochem. Biophys. Res. Commun. 243, 246-252
27. Figueroa, C D., Maciver, A. G. and Bhoola, K. D. (1989) Br. J. Haematol. 72, 321-328
28. Burch, R. M. and DeHaas, C. (1998) Naunyn-Schmiedeberg's Arch. Pharmacol. 342, 189-193
29. Cruwys, S. C. et al. (1994) Br. J. Pharmacol. 113, 940-944
30. Vianna, R. M. J. and Calixto, J. B. (1998) Br. J. Pharmacol. 123, 281-291
31. Whalley, E. T. et al. (1992) Agents Actions 38, 482-487
32. Dray, A. and Perkins, M. (1993) Trends Neurosci. 16, 99-104
33. Davis, C. L. et al. (1996) Br. J. Pharmacol. 118, 1469-1476
34. Ahluwalia, A. and Perretti, M. (1996) J. Immunol. 156, 269-274
35. Rajasekariah, P., Warlow, R. S. and Walls, R. S. (1997) Biochem. Mol. Biol. Int. 43, 279-290
36. Gallin, J. I., Goldstein, I. M. and Snyderman, R. (1992) in Inflammation: Basic Principles and Clinical Correlates (Gallin, J. I., Goldstein, I. M. and Snyderman, R., eds), pp. 1-4, Raven Press